The complete program is below. Click the individual session for details on the speaker or session.
Wednesday, November 14 • 1:35pm - 2:05pm
Small Molecules Part 2: Point/Counterpoint: New Tech Bypassing Traditional CM

Sign up or log in to save this to your schedule and see who's attending!

More established pharma companies, through the years, have built a compound management infrastructure for centralized distribution to their research communities. Within this paradigm, synthesized compounds are transferred to Compound Management and then distributed for biological assay testing. A new paradigm is evolving as technologies are now available that enables the distribution of newly synthesized compounds directly to the assay. In this point/counterpoint session, Jeff Chin (Sr. Research Scientist at BMS) and Shree Khunte (Senior Principal Scientist at Pfizer) will discuss the pros and cons of bypassing CM versus having CM between the chemists and the researchers. They will highlight applications as well as points to consider for either paradigms.

avatar for Jefferson Chin

Jefferson Chin

Senior Research Scientist, Bristol-Myers Squibb
avatar for Shree Khunte

Shree Khunte

Senior Principal Scientist, Pfizer, Inc.
Bhagyashree Khunte is a Senior Principal Scientist in the R&D division at Pfizer Inc. with around 20 years of experience in separation sciences. She leads the Discovery Separations group that provides mg to multigram-scale purification support to Medicinal Chemistry therapeutic areas... Read More →

Wednesday November 14, 2018 1:35pm - 2:05pm
Omni Parker House Omni Parker House, Boston, MA 02108, USA
  • Location Press Room